arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ALX ONCOLOGY HOLDINGS INC

ALXO
$1.14 ▼ -0.22 (-16.24%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
32 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
43
Health
Weak
Neutral
auto_awesome

Analytical Summary

ALX ONCOLOGY HOLDINGS INC shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $154.6M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -9.7% ↘
FCF / Share $-0.12 ↗
Trailing P/E —
Price / Book 1.2x
FCF Yield —
Debt / Equity 0.07
info Valuation on last close. End-of-day price, Nov 5, 2026.

32-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0% —
Net Income Profit after all expenses
$-17.93M
↑ +41.7% —
Operating Margin Operating profit as % of sales
-241.6%
↑ +25.3% —
FCF / Share Free cash flow per share
$-0.12
↑ +33.7% —
Long-Term Debt Long-term obligations
$10.20M
↑ +15.1% —

Health Breakdown

Financial Health ↑
36
Cash Quality →
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 9 years · 32 quarters